Journal article

Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate

Sophie N Lee, Jenna Kraska, Melissa Papargiris, Linda Teng, Birunthi Niranjan, Johanna Hammar, Andrew Ryan, Mark Frydenberg, Nathan Lawrentschuk, Ralf Middendorff, Stuart J Ellem, Michael Whittaker, Gail P Risbridger, Betty Exintaris



Pharmacotherapies for the treatment of Benign Prostatic Hyperplasia (BPH) are targeted at reducing cellular proliferation (static component) or reducing smooth muscle tone (dynamic component), but response is unpredictable and many patients fail to respond. An impediment to identifying novel pharmacotherapies is the incomplete understanding of paracrine signalling. Oxytocin has been highlighted as a potential paracrine mediator of BPH. To better understand oxytocin signalling, we investigated the effects of exogenous oxytocin on both stromal cell proliferation, and inherent spontaneous prostate contractions using primary models derived from human prostate tissue. We show that the Oxytocin Re..

View full abstract